In a pooled analysis of 10 studies including 1584 patients, the results identified significant differences in biomarkers on admission in patients who survived from those who did not. In the study, biomarkers were significantly higher comprised of white blood cell count, neutrophil count, C-reactive protein, high sensitivity C-reactive protein, procalcitonin, ferritin, D-dimer, interleukin-6, lactate dehydrogenase, creatine kinase, prothrombin time, aspartate aminotransferase, total bilirubin, and creatinine. It was also seen that patients who could not survive had significantly low lymphocyte count, platelet count, and albumin. It is an important study as there is limited information regarding the role of biomarker levels to predict mortality in patients with the COVID 19 disease pandemic. 

Resource: Loomba RS, et al. Annals of clinical biochemistry: International journal of laboratory medicine. May 14, 2021. https://doi.org/10.1177/00045632211014244